Apr. 12 at 9:51 AM
$ZVRA The market may react this week, to Middle East happenings, but do not let them fool you about Zevra. Here’s why:
• MIPLYFFA is a small-molecule drug (not a biologic or complex biologic).
• Its active pharmaceutical ingredient (arimoclomol) is a synthetic compound that is manufactured through standard chemical synthesis routes.
• The primary manufacturing and supply chain for arimoclomol is handled by established partners in Europe and the United States, with secondary sourcing from India and China (standard for most small-molecule drugs).
• There is no public disclosure, regulatory filing, or supply-chain report from Zevra indicating reliance on active pharmaceutical ingredients (APIs) or critical raw materials from Iran, Israel, Turkey, or Egypt.
So do not give in to panic selling. Our investment in Zevra, IMO, is a safe-haven. As previously stated, the world needs Miplyffa, and it’s need will obviously keep expanding, as awareness of it’s existence grows.
